These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 12813977)

  • 21. Safety of very tight glucose control in type 2 diabetes in question.
    Idris I
    Diabetes Obes Metab; 2008 May; 10(5):438. PubMed ID: 18431839
    [No Abstract]   [Full Text] [Related]  

  • 22. PPAR gamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone.
    Zinman B
    Diabetes Obes Metab; 2001 Aug; 3 Suppl 1():S34-43. PubMed ID: 11685828
    [No Abstract]   [Full Text] [Related]  

  • 23. Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone.
    Miyazaki Y; Mahankali A; Matsuda M; Glass L; Mahankali S; Ferrannini E; Cusi K; Mandarino LJ; DeFronzo RA
    Diabetes Care; 2001 Apr; 24(4):710-9. PubMed ID: 11315836
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Cardiac risk in post-infarct patients. What allows the diabetic heart to beat longer? (interview by Dr. Judith Neumaier)].
    Mehnert H
    MMW Fortschr Med; 2006 May; 148(21):58. PubMed ID: 16796194
    [No Abstract]   [Full Text] [Related]  

  • 25. Glucose supply and insulin demand dynamics of antidiabetic agents.
    Monte SV; Schentag JJ; Adelman MH; Paladino JA
    J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetes.
    Rosenstock J; Rood J; Cobitz A; Biswas N; Chou H; Garber A
    Diabetes Obes Metab; 2006 Nov; 8(6):650-60. PubMed ID: 17026489
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing diabetes management through glucose profiling: a case-based approach.
    Streja DA
    Prim Care Diabetes; 2008 Dec; 2(4):167-73. PubMed ID: 18786873
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imaging.
    Nitta Y; Tahara N; Tahara A; Honda A; Kodama N; Mizoguchi M; Kaida H; Ishibashi M; Hayabuchi N; Ikeda H; Yamagishi S; Imaizumi T
    JACC Cardiovasc Imaging; 2013 Nov; 6(11):1172-82. PubMed ID: 24229770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes.
    Raskin P; Rappaport EB; Cole ST; Yan Y; Patwardhan R; Freed MI
    Diabetologia; 2000 Mar; 43(3):278-84. PubMed ID: 10768088
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Case study 1: exploring the pharmacologic agents for treatment of type 2 diabetes.
    Martin CL
    Diabetes Educ; 2007; 33 Suppl 1():6S-13S. PubMed ID: 17272803
    [No Abstract]   [Full Text] [Related]  

  • 32. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
    Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
    Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
    [No Abstract]   [Full Text] [Related]  

  • 33. [Glycemic control and cardiovascular benefit: What do we know today?].
    Hanefeld M; Schönauer M; Forst T
    Dtsch Med Wochenschr; 2010 Feb; 135(7):301-7. PubMed ID: 20146161
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes.
    Phillips LS; Grunberger G; Miller E; Patwardhan R; Rappaport EB; Salzman A;
    Diabetes Care; 2001 Feb; 24(2):308-15. PubMed ID: 11213884
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reduced skeletal muscle uncoupling protein-3 content in prediabetic subjects and type 2 diabetic patients: restoration by rosiglitazone treatment.
    Schrauwen P; Mensink M; Schaart G; Moonen-Kornips E; Sels JP; Blaak EE; Russell AP; Hesselink MK
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1520-5. PubMed ID: 16384852
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Intensive blood sugar treatment in type 2 diabetics: no evidence for increased mortality in the ADVANCE study compared with ACCORD study].
    Füchtenbusch M; Hummel M
    MMW Fortschr Med; 2008 Apr; 150(17):42-4. PubMed ID: 18510157
    [No Abstract]   [Full Text] [Related]  

  • 37. US regulators relax restrictions on rosiglitazone.
    McCarthy M
    BMJ; 2013 Nov; 347():f7144. PubMed ID: 24286989
    [No Abstract]   [Full Text] [Related]  

  • 38. Type 2 diabetes: target HbA1c of about 7%.
    Prescrire Int; 2009 Aug; 18(102):177. PubMed ID: 19746575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetes.
    Tran MT; Navar MD; Davidson MB
    Diabetes Care; 2006 Jun; 29(6):1395-6. PubMed ID: 16732030
    [No Abstract]   [Full Text] [Related]  

  • 40. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus.
    Rosenblatt S; Miskin B; Glazer NB; Prince MJ; Robertson KE;
    Coron Artery Dis; 2001 Aug; 12(5):413-23. PubMed ID: 11491207
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.